ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT00481091
- Locations
- 🇺🇸
Dana-Farber Cancer Institute /ID# 5547, Boston, Massachusetts, United States
🇬🇧Leicester Royal Infirmary /ID# 15081, Leicester, England, United Kingdom
🇺🇸Moores Cancer Center at UC San Diego /ID# 5566, La Jolla, California, United States
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 86
- Registration Number
- NCT00445198
- Locations
- 🇺🇸
Site Reference ID/Investigator# 13605, Peoria, Arizona, United States
🇺🇸Site Reference ID/Investigator# 4718, Sacramento, California, United States
🇺🇸Site Reference ID/Investigator# 11942, Los Angeles, California, United States
A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 141
- Registration Number
- NCT00443391
- Locations
- 🇺🇸
Site Reference ID/Investigator# 6109, Mesa, Arizona, United States
🇺🇸Site Reference ID/Investigator# 6100, Lafayette, California, United States
🇺🇸Site Reference ID/Investigator# 6107, San Diego, California, United States
Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis
- Conditions
- Endometriosis
- Interventions
- Drug: Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)Drug: Placebo to DMPA-SC
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 252
- Registration Number
- NCT00437658
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
- Conditions
- Lymphoid MalignanciesMantle Cell LymphomaChronic Lymphoid LeukemiaNon-Hodgkin's LymphomaFollicular LymphomaPeripheral T-cell Lymphoma
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 81
- Registration Number
- NCT00406809
- Locations
- 🇺🇸
Site Reference ID/Investigator# 2627, New York, New York, United States
🇺🇸Site Reference ID/Investigator# 2614, New York, New York, United States
🇺🇸Site Reference ID/Investigator# 4997, Los Angeles, California, United States
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 40
- Registration Number
- NCT00401570
- Locations
- 🇬🇧
Site Reference ID/Investigator# 70536, Manchester, United Kingdom
🇬🇧Site Reference ID/Investigator# 70534, Glasgow, United Kingdom
🇺🇸Site Reference ID/Investigator# 70538, Pittsburgh, Pennsylvania, United States
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
- Conditions
- Severe Motor FluctuationsDyskinesiasParkinson's Disease
- Interventions
- Drug: Levodopa-carbidopa intestinal gelDevice: CADD-Legacy® 1400 ambulatory infusion pumpDevice: PEG tubeDevice: J-tube
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 62
- Registration Number
- NCT00360568
- Locations
- 🇺🇸
Site Reference ID/Investigator# 45834, Fountain Valley, California, United States
🇺🇸Site Reference ID/Investigator# 45836, Port Charlotte, Florida, United States
🇺🇸Site Reference ID/Investigator# 45862, Baltimore, Maryland, United States
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Drug: Placebo gelDrug: Placebo (PBO) oral capsulesDevice: CADD-Legacy® 1400 ambulatory infusion pumpDevice: PEG tubeDevice: J-tube
- First Posted Date
- 2006-07-28
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 36
- Registration Number
- NCT00357994
- Locations
- 🇺🇸
Site Reference ID/Investigator# 45721, Bradenton, Florida, United States
🇺🇸Site Reference ID/Investigator# 45740, Baltimore, Maryland, United States
🇺🇸Site Reference ID/Investigator# 45739, St. Louis, Missouri, United States
Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Drug: Levodopa-carbidopa intestinal gelDevice: CADD-Legacy® 1400 ambulatory infusion pumpDevice: PEG tubeDevice: J-tube
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 354
- Registration Number
- NCT00335153
- Locations
- 🇺🇸
Site Reference ID/Investigator# 50044, Cleveland, Ohio, United States
🇺🇸Site Reference ID/Investigator# 50059, Fountain Valley, California, United States
🇺🇸Site Reference ID/Investigator# 50048, Los Angeles, California, United States
A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer
- Conditions
- Lung CancerNSCLCNon-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 165
- Registration Number
- NCT00297089
- Locations
- 🇺🇸
Site Reference ID/Investigator# 3353, Chicago, Illinois, United States
🇺🇸Site Reference ID/Investigator# 6006, Philadelphia, Pennsylvania, United States
🇺🇸Site Reference ID/Investigator# 2411, Fort Lauderdale, Florida, United States